[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Skin Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100648094","for-an-investigator-led-hair-study-comparing-between-healthy-and-hair-loss-volunteers-100648094",false,"NCT07716748","For an Investigator-led Hair Study Comparing Between Healthy and Hair Loss Volunteers","Beyond the Scalp: A Multi-Omic Microbiome Analysis in Androgenetic Alopecia Patients at Baseline and After Oral Minoxidil Treatment Versus Healthy Controls","Inclusion Criteria:\n\n1. Male volunteer from 21 to 45 years old\n2. Volunteer with BMI between 18.5 to 30 kg\u002Fm2\n3. Volunteer willing and able to fulfill the study requirements and schedule\n4. Volunteer willing to give their stool sample, as well as swabs, follicles, and blood.\n5. Volunteer informed about the study objectives and procedures, and able to understand them\n6. Volunteer who has given written informed consent\n\nVolunteers in the healthy control panel must satisfy the following criteria:\n\n1. Volunteer in overall good health\n2. Volunteer with no diagnosis of hair loss or other condition or treatment susceptible to impact hair count and microbiome.\n\nVolunteers in the AGA panel must satisfy the following criteria:\n\n1. Volunteer diagnosed with Androgenetic Alopecia grade III Vertex to V on the Hamilton-Norwood scale\n2. Volunteer willing to restrain from the use of any additional hair loss oral and topical pharmaceuticals (ex: topical minoxidil) over the course of the study\n3. Volunteer eligible to undergo oral minoxidil treatment, with no contra-indication\n\nExclusion Criteria:\n\n1. Volunteer with severe gastro-intestinal symptoms (including gluten and lactose intolerance)\n2. Volunteer with auto-immune disease, diabetes; hyper or hypo-thyroidism ; chronic kidney failure\n3. Volunteer with diagnosis of scalp-related disease such as folliculitis, lichen planopilaris, folliculitis decalvans, tinea capitis, head lice, or seborrheic dermatitis\n4. Volunteer undergoing hypertension treatment\n5. Volunteer who undertook any oral anti-hair loss pharmaceutical treatment in the past 3 months (e.g. Finasteride)\n6. Volunteer who undertakes any hormone-disrupting drug\n7. Volunteer who used topical minoxidil or other pharmaceutical-grade topical hair restorers in the past 3 months\n8. Volunteer with a total dandruff score above 1 on the L'Oreal Dandruff scale.\n9. Volunteer who used perms or hair dyes in the past 2 months\n10. Volunteer who underwent scalp reduction or hair transplant procedures\n11. Volunteer who declares to be deprived of freedom by administrative or legal decision\n12. Volunteer who cannot be contacted by phone in case of emergency\n13. Volunteer having currently participating in another clinical study\n14. Volunteer who used antibiotics or antifungal medication (topical to scalp and systemic) in the past 4 weeks\n15. Volunteer who used probiotics supplements in the past 4 weeks. (dietary probiotics such as yogurt, kefir, and kimchi are acceptable)\n16. Volunteer who follows a non-conventional diet (e.g. vegan, ketogenic, strict intermittent fasting diets)\n\nNon-inclusion Criteria:\n\n1. Volunteer diagnosed with HIV, Hepatitis C, Hepatitis B\n2. Volunteer with severe gastro-intestinal symptoms (including gluten and lactose intolerance)\n3. Volunteer with auto-immune disease, diabetes; hyper or hypo-thyroidism ; chronic kidney failure\n4. Volunteer with diagnosis of scalp-related disease such as folliculitis, lichen planopilaris, folliculitis decalvans, tinea capitis, head lice, or seborrheic dermatitis\n5. Volunteer undergoing hypertension treatment\n6. Volunteer who undertook any oral anti-hair loss pharmaceutical treatment in the past 3 months (e.g. Finasteride)\n7. Volunteer who undertakes any hormone-disrupting drug\n8. Volunteer who used topical minoxidil or other pharmaceutical-grade topical hair restorers in the past 3 months\n9. Volunteer with a total dandruff score above 1 on the L'Oreal Dandruff scale.\n10. Volunteer who used perms or hair dyes in the past 2 months\n11. Volunteer who underwent scalp reduction or hair transplant procedures\n12. Volunteer who declares to be deprived of freedom by administrative or legal decision\n13. Volunteer who cannot be contacted by phone in case of emergency\n14. Volunteer having currently participating in another clinical study\n15. Volunteer who used antibiotics or antifungal medication (topical to scalp and systemic) in the past 4 weeks\n16. Volunteer who used probiotics supplements in the past 4 weeks. (dietary probiotics such as yogurt, kefir, and kimchi are acceptable)\n17. Volunteer who follows a non-conventional diet (e.g. vegan, ketogenic, strict intermittent fasting diets)\n18. Volunteer who used anti-dandruff shampoo in the past 4 weeks (For example, commonly used brands for anti-dandruffs could be : Head \\& Shoulders, Sebamed, Clear, Dove, Pantene, L'OREAL, Vichy Dercos)",true,"MALE","21 Years","45 Years",{"count":21,"type":22},66,"ESTIMATED","OBSERVATIONAL","This study is to evaluate differences in the gut and follicle\u002Fscalp microbiome signature in AGA compared to a non-AGA population. Also, to investigate differences in inflammation and other biomarkers in AGA compared to non-AGA population at baseline and after a successful treatment",[26],"Hair Loss","NOT_YET_RECRUITING","2026-07-16",{"date":30,"type":31},"2026-07-21","ACTUAL",{"date":33,"type":22},"2026-08",{"date":35,"type":22},"2028-01",{"name":37,"class":38},"National Skin Centre","NETWORK",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":16,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":51,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100624592","non-interventional-translational-study-in-mild-moderate-and-severe-acne-patients-100624592","NCT07411638","Non-interventional Translational Study in Mild, Moderate and Severe Acne Patients","VBE00011","INCLUSION CRITERIA:\n\nAGE I01: Aged 18 to 25 years on the day of inclusion.\n\nTYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS\n\nI02: Participants with a formal diagnosis of either:\n\n* Mild facial acne vulgaris defined as Investigator's Global Assessment (IGA) of 2, or\n* Moderate facial acne vulgaris defined as IGA score of 3, or\n* Severe facial acne vulgaris defined as IGA score of 4, or\n* Healthy volunteers without acne defined as IGA score of 0.\n\nINFORMED CONSENT I03: Informed consent form has been signed and dated by participant capable of providing informed consent.\n\nNote: For minor participants, informed consent form must also be signed and dated by the parent(s) or another legally acceptable representative(s).\n\nOTHER INCLUSIONS I04: Participant or participant and parent(s)\u002Flegally acceptable representative(s) are able to attend all scheduled visits and to comply with all study procedures.\n\nEXCLUSION CRITERIA\n\nParticipants are not eligible for the study if any of the following criteria are met:\n\nMEDICAL CONDITIONS E01: Thrombocytopenia, presence of bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating blood sampling, currently or previously suffering from any immune disorder.\n\nE02: Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion.\n\nE03: Active nodulocystic acne, acne conglobata, acne fulminans, secondary acne (eg, chloracne, drug-induced acne) or other forms of acne (eg, acne mechanica).\n\nE04: Skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the study intervention or requires use of interfering topical, systemic, or surgical therapy.\n\nE05: Excessive facial hair, facial tattoos, facial skin disorders, skin reactions that may interfere with the study assessments in the investigator's opinion (including - but not limited to - actinic keratosis, eczema, psoriasis, seborrheic dermatitis, rosacea, acute or recent sunburn) or skin infection.\n\nE06: Alcohol, prescription drug, or substance abuse that, in the opinion of the investigator, might interfere with the study conduct or completion.\n\nE07: Self-reported or documented seropositivity for human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus.\n\nE08: Moderate or severe acute illness\u002Finfection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C \\[≥ 100.4°F\\]) on the day of samplings. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.\n\nPRIOR\u002FCONCOMITANT THERAPY:\n\nE09: Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 6 months prior to the study sample collection; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) within 3 months from study sample collection.\n\nE10: Start or switch of hormonal contraceptive use within 12 weeks prior to the study visit.\n\nE11: Previous use of oral isotretinoin. E12: Use of any acne-affecting treatment without an appropriate washout period (antibacterial\u002Fantifungal\u002Fantiseptic medications or topicals). Participants receiving prohibited medications\u002Ftherapies at Screening Visit will have to observe a washout period of 2 to 24 weeks before enrolment to preserve eligibility in the study.\n\nE13: Previous vaccination against C. acnes with an investigational vaccine E14: Receipt of immune globulins, blood or blood-derived products in the past 3 months E15: Pregnant or lactating women\n\nPRIOR\u002FCONCURRENT CLINICAL STUDY EXPERIENCE E16: Participation at the time of study enrolment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.\n\nOTHER EXCLUSIONS:\n\nE17: Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.\n\nE18 Identified as an Investigator or employee of the Investigator or study centre with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.","ALL","18 Years","25 Years",{"count":50,"type":22},200,"1 Day","This study aims to uncover the specific immunopathology, microbiome and pathophysiology of acne vulgaris in people living in a tropical climate such as Singapore. This is a largely unexplored population in terms of acne pathogenesis, and will lead to population-specific interventions for the management of acne vulgaris.",[54],"Acne","2026-02-06",{"date":57,"type":31},"2026-02-17",{"date":59,"type":22},"2026-02-15",{"date":61,"type":22},"2029-02-14",{"name":37,"class":38},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":16,"sex":46,"minAge":18,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100526762","phase-2-comparing-the-effect-of-sisparc-microneedle-patch-versus-sisparcsilr4a-microneedle-patch-on-post-surgical-scars-100526762","NCT06138964","Comparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars","Randomized Intra-individually Controlled Double-blinded Trial Comparing Effect of Small Interfering RNA Against SPARC (siSPARC) Microneedle Patch Versus Small Interfering RNA Against SPARC and IL4-RA (siSPARC + siLR4A) Microneedle Patch on Appearance of Post-surgical Scars","Inclusion Criteria:\n\n* Adult\n* Age 21-75\n* 2 weeks (+\u002F- 7 days) after surgical operation with incision into the dermis\n* Post-stitch removal when stitches were applied\n* Wound closure\u002Funion achieved\n\nExclusion Criteria:\n\n* Pregnant or lactating participant\n* Participants with wound infection\n* Participants assessed to be uncooperative or unable to self-administer the interventions\n* Participants with known contact allergy to ingredients in the patch formulation (comprising hyaluronic acid, siRNA and glue) and\u002For isopropyl alcohol\n* Participants who are unable to personally consent (for e.g., cognitively impaired)","75 Years",{"count":72,"type":22},50,"INTERVENTIONAL",[75],"PHASE2","This randomized, double-blind controlled study aims to compare the effect on appearance of post- surgical scars between daily application of siSPARC microneedle patch versus siSPARC + siLR4A microneedle patches. These are patches comprising short microneedles embedded with hydrolysed RNA (siRNAs).",[78,79,80],"Keloid","Wound Heal","Wound","RECRUITING","2024-06-20",{"date":84,"type":31},"2024-06-24",{"date":86,"type":31},"2023-11-14",{"date":88,"type":22},"2024-11-14",{"name":37,"class":38},1,""]